<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="19595">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02851797</url>
  </required_header>
  <id_info>
    <org_study_id>DSC/14/2357/48</org_study_id>
    <nct_id>NCT02851797</nct_id>
  </id_info>
  <brief_title>Clinical Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy</brief_title>
  <official_title>Randomised, Double Blind, Placebo Controlled, Multicentre Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Italfarmaco</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>inVentiv Health Clinical</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Italfarmaco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      it is a randomised, double blind, parallel group, placebo controlled study. A total of 213
      male ambulant subjects will be randomised 2:1 (givinostat:placebo).

      Subjects will be stratified for their concomitant use of steroids in 4 strata:

        1. Deflazacort daily regimen

        2. Deflazacort intermittent regimen

        3. Other steroids daily regimen

        4. Other steroids intermittent regimen. The study duration is planned for 19 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Givinostat or placebo oral suspension (10 mg/mL) will be administered orally as 2 oral doses
      daily while the subject is in fed state, according to the child's weight.

      Study drug should be permanently stopped if any of the following occur:

        -  severe drug-related diarrhoea;

        -  any drug-related Serious Adverse Event;

        -  QTcF &gt;500 msec;

        -  platelets count ≤50 x 109/L.

      Study drug should be temporarily stopped if any of the following occur:

        -  platelets count &lt;75 x 109/L but &gt;50 x 109/L (the treatment should be temporarily
           stopped and a platelets count has to be performed and re-tested until platelets will be
           normalized);

        -  moderate or severe diarrhoea.

      In case the study drug was temporarily stopped, the study drug can be resumed at a level 1/3
      smaller than the one at which the Adverse Event leading to temporary stop occurred, once
      platelets are normalized or diarrhoea is mild (if treatment was stopped for moderate or
      severe diarrhoea).

      Two interim analyses are planned and will be conducted by the IDMC in order to ensure study
      integrity.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2017</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>mean change in 4 standard stairs climb</measure>
    <time_frame>18 months</time_frame>
    <description>the primary endpoint is the mean change in 4 standard stairs climb test results before and after 18 months of treatment of givinostat versus placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Other functional test as 6MWT</measure>
    <time_frame>18 months</time_frame>
    <description>the mean change in 6MWT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to rise from floor</measure>
    <time_frame>18 months</time_frame>
    <description>the mean change in time to rise from floor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Magnetic Resonance Spetroscopy</measure>
    <time_frame>18 months</time_frame>
    <description>the mean change in fat fraction of vastus lateralis muscles at MRS</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">213</enrollment>
  <condition>Duchenne Muscular Dystrophy</condition>
  <arm_group>
    <arm_group_label>givinostat</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Givinostat oral suspension (10 mg/mL) twice daily in a fed state</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo oral suspension (10 mg/mL) twice daily in a fed state</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>givinostat</intervention_name>
    <description>suspension of givinostat (10 mg/mL)</description>
    <arm_group_label>givinostat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>suspension manufactured to mimic givinostat</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Are an ambulant male aged ≥6 years at randomisation with DMD characteristic clinical
             symptoms or signs (e.g., proximal muscle weakness, Gowers' maneuver, elevated serum
             creatinine kinase level) already present at screening;

          2. Have DMD diagnosis confirmed by genetic testing;

          3. Are able to give informed assent and/or consent in writing signed by the subject
             and/or parent/legal guardian (according to local regulations);

          4. Are able to complete 2 Four Stairs Climb test (4SC) screening assessments; the
             results of these tests must be within ±1 second of each other;

          5. Have the mean of 2 screening 4SC assessments ≤8 seconds;

          6. Have time to rise from floor of &lt;10 seconds at screening;

          7. Have manual muscle testing (MMT) of quadriceps at screening ≥ Grade 3;

          8. Are eligible according to the protocol-specified functional algorithm* predictive of
             vastus lateralis muscle fat fraction (VL MFF) that should be in the range &gt;10% but
             &lt;30% (see section 4.2.3);

          9. Have used systemic corticosteroids for a minimum of 6 months immediately prior to the
             start of study treatment, with no significant change in dosage or dosing regimen
             (excluding changes related to body weight change) for a minimum of 6 months
             immediately prior to start of study treatment and a reasonable expectation that
             dosage and dosing regimen will not change significantly for the duration of the
             study.

               -  The protocol-specific functional algorithm will consider results relevant Four
                  stairs climb test and knee extensor peak torque measurement.

        Exclusion Criteria:

          1. Have exposure to another investigational drug within 3 months prior to the start of
             study treatment;

          2. Have exposure to idebenone within 3 months prior to the start of study treatment;

          3. Have exposure to any dystrophin restoration product (e.g., Ataluren, Exon skipping)
             within 6 months prior to the start of study treatment;

          4. Use of any pharmacologic treatment, other than corticosteroids, that might have had
             an effect on muscle strength or function within 3 months prior to the start of study
             treatment (e.g., growth hormone); Vitamin D, calcium, and any other supplements will
             be allowed;

          5. Have surgery that might have an effect on muscle strength or function within 3 months
             before study entry or planned surgery at any time during the study;

          6. Ankle joint contractures due to a fixed loss of ≥10 degrees of dorsiflexion from
             plantagrade assuming a normal range of dorsiflexion of 20 degree;

          7. Change in contracture treatment such as serial casting, contracture control devices,
             night splints, stretching exercises (passive, active, self) within 3 months prior to
             enrollment, or expected need for such intervention during the study;

          8. Have presence of other clinically significant disease, which, in the Investigator's
             opinion, could adversely affect the safety of the subject, making it unlikely that
             the course of treatment or follow-up would be completed, or could impair the
             assessment of study results;

          9. Have a diagnosis of other neurological diseases or presence of relevant somatic
             disorders that are not related to DMD;

         10. Have platelets count at screening &lt; Lower Limit of Normal (LLN);

         11. Have symptomatic cardiomyopathy or heart failure (New York Heart Association Class
             III or IV) or left ventricular ejection fraction &lt;50% at screening;

         12. Have a current or history of liver disease or impairment;

         13. Have inadequate renal function, as defined by serum Cystatin C &gt;2 x the upper limit
             of normal (ULN);

         14. Have a positive test for hepatitis B surface antigen, hepatitis C antibody, or human
             immunodeficiency virus at screening;

         15. Have a baseline QTcF &gt;450 msec, or history of additional risk factors for torsades de
             pointes (e.g., heart failure, hypokalemia, or family history of long QT syndrome);

         16. Have a psychiatric illness/social situations rendering the potential subject unable
             to understand and comply with the muscle function tests and/or with the study
             protocol procedures;

         17. Have any known allergic reaction to givinostat or any of its excipients.

             For the subgroup of subjects who will undergo MRI and MRS (i.e., MR Cohort):

         18. Have contraindications to MRI or MRS (e.g., claustrophobia, metal implants, or
             seizure disorder).
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Paolo Bettica, MD</last_name>
    <phone>+39 0264432511</phone>
    <email>p.bettica@italfarmaco.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sara Cazzaniga, Biology</last_name>
    <phone>+39 0264432524</phone>
    <email>s.cazzaniga@italfarmaco.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California - Davis Medical Center - Devis Physical Medicin &amp; Rehabilitation</name>
      <address>
        <city>Davis</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Craig McDonald, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>David Geffen School of Medicine - UCLA Neurology</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Perry Shieh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rady Children's Hospital center - UCSD Department of Neuroscience</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Carla Grosmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Michele Yang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Connecticut Children's Medical Center - Division Neurology</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Gyula Acsadi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Child Health Research Institute - Department of Pediatrics</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Barry Byrne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Hospital</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32827</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Richard Finkel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa Children's Hospital</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Katherine Mathews, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wayne State University - University Pediatrics - Children's Hospital of Michigan</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Huiyuan Jiang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota - Department of Neurology</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Peter Manousakis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine in St Louis - Department of Neurology</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Anne Connolly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shriners Hospitals for Children</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Erika Finanger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Gihan Tennekoon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital of Richmond at Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jean Harper, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Leuven, Neuromuscular Reference Centre, Child Neurology</name>
      <address>
        <city>Leuven</city>
        <zip>03000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Nathalie Goemans, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de La Citadelle, Centre de Référence des Maladies Neuromuscolaires (CRMN)</name>
      <address>
        <city>Liege</city>
        <zip>04000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Laurent Servais, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alberta Children's Hospital</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3B6A8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jean Mah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of British Columbia, Children's and Womens Health Centre of BC Branch</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H 3V4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Kathryn Selby, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Holland Bloorview Kids Rehabilitation Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4G1R8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Laura McAdam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes - Hotel-Dieu - Hopital Nord Laennec, rez-de-chausse haut ail Ouest</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Yann Pereon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Armand Trousseau I-Motion, Plateforme d'essais cliniques pédiatriques</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Teresa Gidaro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Essen - Kinder und Jugendmedizin Neuropadiatrie</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ulrike Schara, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinik un Policlinik fur Kinder und Jugendmedizin - Universitatsklinikum Hamburg Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jessika Johanssen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum der Uniersitat Munchen - Campus Innenstadt</name>
      <address>
        <city>Munchen</city>
        <zip>80337</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Wolfgang Muller-Felber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto G.Gaslini, U.O.S.D. Centro Traslazionale di Miologia e Patologie Neurodegenerative</name>
      <address>
        <city>Genova</city>
        <zip>16147</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Claudio Bruno, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O.U. Policlinico G. Martino, U.O.C. Neurologia e Malattie Neuromuscolari</name>
      <address>
        <city>Messina</city>
        <zip>98125</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Giuseppe Vita, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, UOS di Neurologia Pediatrica</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Giacomo Comi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Pediatrico Bambin Gesù, Malattie Neuromuscolari e Neurodegenerative</name>
      <address>
        <city>Roma</city>
        <zip>00146</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Enrico Bertini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario &quot;A.Gemelli&quot;, UOC Neuropsichiatria Infantile</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Eugenio Mercuri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center LUMC</name>
      <address>
        <city>Leiden</city>
        <zip>ZH 2300 RC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Erik Niks, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radboud University Medical Centre</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Imelda de Groot, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan de Déu - Neuromuscular Pathology Unit</name>
      <address>
        <city>Esplugas de Llobregat</city>
        <state>Barcelona</state>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Andres Nascimento, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Materno-Infantil - Passeig de la Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Francina Munell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital 12 de Octubre - Hospital Materno Infantil</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ana Camacho Salas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politécnic de la Fe - Servicio Neurologia</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Juan Jesus Vilchez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alder Hey Children's Hospital NHS Trust</name>
      <address>
        <city>Liverpool</city>
        <zip>L12 2AP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Stefan Spinty, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCL Great Ormond Street Institute of Child Health, Dubowitz Neuromuscular Centre and MRC Centre for NMD</name>
      <address>
        <city>London</city>
        <zip>EC1N 1EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Francesco Muntoni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The John Walton Muscular Dystrophy Research Centre - Freeman Hospital - Newcastle University - Institute of Genetic Medicine</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE1 3BZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Michela Guglieri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Robert Jones and Agnes Hunt Orthopaedic Hospital - NHS Foundation Trust</name>
      <address>
        <city>Oswestry</city>
        <zip>SY 10 7AG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Tracey Willis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 29, 2017</lastchanged_date>
  <firstreceived_date>July 27, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
